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Introduction: The establishment of drug resistance following treatment with chemotherapeutics is strongly
associated with poor clinical outcome in patients, and drugs that target chemoresistant tumors have the potential
to increase patient survival. In an effort to identify biological pathways of chemoresistant breast cancers that can be
targeted therapeutically, a small molecule screen utilizing metastatic patient-derived breast cancer cells was
conducted; from this previous report, the cytotoxic small molecule, C-6, was identified for its ability to selectively
kill aggressive breast cancer cells in a caspase-independent manner. Here, we describe the cellular and molecular
pathways induced following C-6 treatment in both normal and breast cancer cell lines.
Methods: Transcriptome analyses and protein expression experiments were used to measure endoplasmic reticulum
(ER) stress following C-6 treatment. Studies utilizing transmission electron microscopy and metabolomic profiling were
conducted to characterize mitochondrial morphology and function in C-6-treated cells. Oxygen consumption rates and
oxidative stress were also measured in breast cancer and normal mammary epithelial cells following treatment with
the small molecule. Finally, structural modifications were made to the molecule and potency and cancer selectivity
were evaluated.
Results: Treatment with C-6 resulted in ER stress in both breast cancer cells and normal mammary epithelial cells. Gross
morphological defects were observed in the mitochondria and these aberrations were associated with metabolic
imbalances and a diminished capacity for respiration. Following treatment with C-6, oxidative stress was observed in three
breast cancer cell lines but not in normal mammary epithelial cells. Finally, synthetic modifications made to the small
molecule resulted in the identification of the structural components that contribute to C-6’s cancer-selective phenotype.
Conclusions: The data reported here implicate mitochondrial and ER stress as a component of C-6’s biological activity
and provide insight into non-apoptotic cell death mechanisms; targeting biological pathways that induce mitochondrial
dysfunction and ER stress may offer new strategies for the development of therapeutics that are effective against
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The efficacy of widely used cancer chemotherapeutics is
frequently limited by side effects resulting from narrow
therapeutic windows between a drug’s beneficial anticancer
activity and its general cytotoxicity. An additional limitation
of widely used anticancer drugs is the development of mul-
tidrug chemoresistance [1]. It has therefore been an interest
of our laboratories to identify novel small molecules that
selectively kill cancer cells, and use these compounds as
tools to define biological pathways necessary for the viabil-
ity of breast cancer cells. We previously reported the identi-
fication of such a molecule, C-6, and established its ability
to kill, in a caspase-independent manner, metastatic pri-
mary cells from patients with chemoresistant breast cancer
[2]. Herein, we report the results of studies on the biological
activity of C-6 and describe structure-activity relationships
for the molecule’s cancer-selective cytotoxicity.
Methods
Cell lines
MCF-7, MCF-10A, and T47D cells were a generous gift
from Andrea Bild at the University of Utah; MDA-MB-
231 cells were obtained directly from the American Type
Culture Collection (ATCC). All cell lines were authenti-
cated within six months of manuscript preparation by
the ATCC in conjunction with Promega (Madison, WI,
USA) using short tandem repeat analysis.
Tissue culture
MCF-10A and MCF-7 cells were cultured with Dulbecco’s
modified Eagle’s medium (DMEM)/F12 media containing
2.5 mM L-glutamine and 15 mM HEPES buffer (Life
Technologies, Grand Island, NY, USA). MDA-MB-231
and T47D cells were cultured with RPMI-1640 medium
containing 2.5 mM L-glutamine and 25 mM HEPES buf-
fer (Life Technologies). All cells were cultured at 37°C
with 5% CO2. For standard culture conditions, medias
were supplemented with 10% fetal bovine serum (FBS)
(heat inactivated, HyClone, Logan, UT, USA) penicillin-
streptomycin-glutamine, 5.0 μg/mL of insulin-transferrin-
selenium-X (ITS-X) (Life Technologies), and 2.5 nM
epidermal growth factor (EGF), recombinant human (BD
Biosciences, San Jose, CA, USA). In the case of treatment
with C-6 or its analogs, low serum medias were used (2%
fetal bovine serum).
Reagents and antibodies
Preparation procedures and characterization data for C-6
and its analogs can be found in a supplementary file
(Additional file 1). The following primary antibodies were
purchased from Cell Signaling (Danvers, MA, USA):
CHOP, GRP78, p-EIF2α, pan-EIF2α, p-JNK, and pan-JNK.
In addition, the vinculin antibody was obtained from
Sigma-Aldrich (St. Louis, MO, USA). Actinomycin D(ACTD) and cycloheximide (CHX) were also obtained
from Sigma-Aldrich.
Dose response assays
All cells were seeded in clear 96-well plates (Costar,
Tewksbury, MA, USA) in 100 μL of their respective media
at densities necessary to achieve 90% confluency at the
end of the 5-day assay. Dimethyl sulfoxide (DMSO) stocks
of the compounds were diluted in their corresponding
media containing 2% FBS and an EP Motion 5075
(Eppendorf North America, Hauppauge, NY, USA) li-
quid handler was utilized to prepare serial dilutions; a
vehicle control corresponding to the highest DMSO
concentration, which did not exceed 0.2% (v/v), was also
prepared. Following an overnight incubation, the media
was aspirated and the cells were treated with the serially
diluted compounds and vehicle control. Every 48 hours,
the drug-containing media was refreshed. Following
5 days of treatment, cell viability was measured using a
CellTiter 96 AQueous One Solution Cell Proliferation
assay per the manufacturer’s protocol (Promega). Blank-
subtracted absorbance values were obtained at 490 nm
and normalized to the DMSO vehicle control wells.
Normalized values were plotted as an average ± standard
deviation of three replicates then analyzed using the dose-
response nonlinear curve fitting function with Prism 6.0
(GraphPad Software, San Diego, CA, USA) to establish
the EC50.
Transcriptome sequencing
In preparation for transcriptome sequencing, MCF-7 cells
were seeded in triplicate in 10-cm tissue culture-treated
plates such that the plate would be 80% confluent at the
time of drug treatment. Cells were treated with 10 mL of
low serum media containing either 30 μM C-6 or DMSO
as a vehicle control for 3 hours. Following the completion
of treatment, RNA was isolated using an RNeasy RNA iso-
lation and purification kit (Qiagen, Hilden, Germany) per
the manufacturer’s protocol.
Library construction was performed using the Illumina
TruSeq Stranded mRNA Sample Preparation Kit (Illumina,
San Diego, CA, USA) as described herein. Briefly, total
RNA (100 ng to 4 ug) was poly-A selected using poly-T
Oligo-attached magnetic beads. Poly-A RNA eluted from
the magnetic beads was fragmented and primed with
random hexamers in preparation for cDNA synthesis. First-
strand reverse transcription was accomplished using Super-
script II Reverse Transcriptase (Invitrogen, Waltham, MA,
USA). Second-strand cDNA synthesis was accomplished
using DNA polymerase I and Rnase H under conditions in
which dUTP is substituted for dTTP, yielding blunt-
ended cDNA fragments. An A-base was added to the
blunt ends in preparation for adapter ligation and to
prevent concatemer formation during the ligation step.
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the A-tailed DNA fragments. Ligated fragments were PCR-
amplified (12 to 15 cycles) under conditions that enabled
only amplification of the first-strand cDNA product. The
PCR-amplified library was purified using Agencourt
AMPure XP beads (Beckman Coulter Genomics, Danvers,
MA, USA). The concentration of the amplified library was
measured with a NanoDrop spectrophotometer and an ali-
quot of the library was resolved on an Agilent 2200 Tape
Station using a D1K or a High Sensitivity D1K assay
(Agilent Technologies, Santa Clara, CA, USA) to define the
size distribution of the sequencing library. Libraries were ad-
justed to a concentration of approximately 10 nM and quan-
titative PCR was performed using the Kapa Library
Quantification Kit (Kapa Biosystems, Boston, MA, USA) to
calculate the molarity of adapter-ligated library molecules.
The concentration was further adjusted following qPCR to
prepare the library for sequence analysis on an Illumina
HiSeq instrument. Following completion of sequencing,
genome alignment was conducted using National Center for
Biotechnology Information (NCBI) build GRch37 and differ-
ential expression analysis was performed using the RNAseq
application [3], which wraps the DESeq Bioconductor pack-
age, and statistical significance was calculated as described
by Anders and Huber [4].
Western blot analyses
For Western blot analyses, cells were lysed in ice-cold
radioimmunoprecipitation assay buffer (pH = 8.0, 50 mM
150 mM NaCl, Tris HCl, 0.1% sodium dodecyl sulfate
(SDS), 0.5% sodium deoxycholate, 1% triton-X-100,) supple-
mented with protease inhibitor cocktail (Sigma-Aldrich),
phosphatase inhibitor cocktail 2 (Sigma-Aldrich), and
1 mM dithiothreitol (DTT) (Sigma-Aldrich). The lysate was
sonicated for 30 seconds with a 450 Sonifier (Branson
Ultrasonics, Danbury, CT, USA) and then centrifuged at
14,000 RPM for 5 minutes at 4°C. A bicinchoninic acid
(BCA) protein assay kit (Pierce, Rockford, IL, USA) was
used to measure the protein concentration and the samples
were subsequently boiled for 5 minutes in 4x SDS Laemmli
buffer. Proteins were separated on SDS polyacrylamide gels
and transferred to a Immobilon-FL PVDF membrane
(EMD Millipore, Billerica. MA, USA). The blots were
blocked in Odyssey Blocking Buffer (LI-COR, Lincoln, NE,
USA) for 1 hour at room temperature, stained with the
primary antibodies overnight at 4°C, then stained with
IR800CW or IR680 anti-mouse or rabbit secondary anti-
bodies (LI-COR) for 1 hour at room temperature. The blots
were imaged with the Odyssey Infrared Imaging System
(LI-COR).
Cell imaging
In tissue culture-treated six-well plates, cells were seeded
at 200,000 cells per well in 3 mL of their respective media.After allowing the cells to recover for 48 hours, the media
was aspirated and replaced with 4 mL of low serum media
containing 30 μM C-6 or DMSO as a vehicle control. For
the duration of the time course imaging, cells were main-
tained at 37°C in a humidified chamber with 5% CO2. Im-
ages were acquired using an IX81 microscope (Olympus,
Center Valley, PA, USA) running Slide Book 5.0 software
(Intelligent Imaging Innovations, Denver, CO, USA). For
experiments utilizing MitoTracker Deep Red FM (Life
Technologies), cells were drug treated for the appropriate
amount of time, then MitoTracker added directly to the
well to achieve a final concentration of 100 nM. The plate
was then incubated for 10 minutes at 37°C, the dye-
containing media discarded and replaced with fresh drug-
containing media, and images acquired.
Transmission electron microscopy
MCF-10A and MCF-7 cells were cultured in 10-cm plates
in preparation for transmission electron microscopy
(TEM) analysis. Following the completion of treatment
with 10 mL of either 30 μM C-6 or a matched DMSO ve-
hicle control, the cells were fixed in a pH 7.4 0.1 M so-
dium cacodylate buffer containing 2.5% glutaraldehyde,
1% paraformaldehyde, 2.4% sucrose, and 8 mM calcium
chloride. After fixation, the cells were rinsed in 0.1 M so-
dium cacodylate buffer and post-fixed in 2% osmium tet-
roxide also in the 0.1 M sodium cacodylate buffer. Cells
were rinsed in type 1 water and en bloc stained in satu-
rated aqueous uranyl acetate. Cells were then dehydrated
in a graded ethanol series, transitioned through acetone,
infiltrated with Embed 812 and acetone, embedded in
fresh Embed 812, and allowed to cure overnight in a 60°C
oven. Plastic sections were cut on a Leica (Wetzlar,
Germany) ultramicrotome with a diamond knife and
placed on copper grids at a thickness of 80 to 100 nm.
Sections were contrasted with saturated aqueous uranyl
acetate followed by Reynold’s lead citrate. They were then
examined on an FEI Tecnai (Hillsboro, OR, USA) T-12
TEM with a LaB6 filament at 120KV. Images were ac-
quired with a Gatan (Pleasanton, CA, USA) Ultrascan
1000 digital camera using Gatan’s digital micrograph.
Metabolomic profiling
Cells were cultured in 10-cm plates and following the
completion of the appropriate drug treatments, the cells
were collected and pelleted, resuspended in 90% MeOH,
and flash frozen in liquid nitrogen. Ten microliters of a
0.2 ug/uL solution of D4-succinate was added to each
sample as an internal control. All GC-MS analysis was
performed with a Waters (Milford, MA, USA) GCT
Premier mass spectrometer fitted with an Agilent 6890
gas chromatograph and a Gerstel (Mülheim an der Ruhr,
Germany) MPS2 autosampler. Dried samples were
suspended in 40 uL of a 40 mg/mL O-methoxylamine
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at 30°C. To the autosampler vials was added 25 uL of this
solution. Ten microliters of N-methyl-N-trimethylsilyltri-
fluoracetamide (MSTFA) was added automatically via the
autosampler and incubated for 60 minutes at 37°C with
shaking. After incubation, 3 uL of a fatty acid methyl ester
standard solution was added via the autosampler then 1 uL
of the prepared sample was injected to the gas chromato-
graph inlet in the split mode with the inlet temperature held
at 250°C. Two GC-MS runs were performed, one at a 10:1
split ratio to detect low-level metabolites and a second at
50:1 split ratio to accurately measure high-concentration
metabolites, which saturate the detector at the 10:1 split ra-
tio. For the 10:1 split ratio analysis, the gas chromatograph
had an initial temperature of 95°C for 1 minute followed by
a 40°C/minute ramp to 110°C and a hold time of 2 minutes.
This was followed by a second 5°C/minute ramp to 250°C, a
third ramp to 350°C, then a final hold time of 3 minutes.
For the 50:1 split ratio analysis, the gas chromatograph had
an initial temperature of 95°C for 1 minute followed by a
40°C/minute ramp to 110°C and a hold time of 2 minutes.
This was followed by a second 25°C/minute ramp to 330°C.
A 30 m Phenomex (Torrance, CA, USA) ZB5-5 MSi col-
umn with a 5-m-long guard column was employed for chro-
matographic separation. Helium was used as the carrier gas
at 1 mL/minute.
Measurement of oxygen consumption and extracellular
acidification rates
Cells were seeded in XF24 V7 culture plates (Seahorse
Bioscience, North Billerica, MA, USA) in 300 μL of their
respective media. After culturing overnight, the media
was aspirated and the cells were treated with 600 μL of
media containing 2% FBS and 30 μM C-6 for 3, 6, 12,
and 24 hours as well as 0.03% (v/v) DMSO (four wells
per condition). The media was aspirated and 600 μL of
unbuffered assay media at pH = 7.4, which consists of
DMEM supplemented with 2 mM GlutaMax-1 (Life
Technologies), 1 mM sodium pyruvate (Sigma-Aldrich),
25 mM glucose (Sigma-Aldrich), and 31.7 mM NaCl
was added and the cells were incubated at 37°C for
1 hour. Utilizing the XF24 Extracellular Flux Analyzer
(Seahorse Biosciences), the baseline oxygen consump-
tion rate (OCR) and extracellular acidification rate
(ECAR) was measured. For the mitochondrial stress test,
oligomycin A (Oligo, Sigma-Aldrich), which inhibits ATP
synthase, was subsequently added to a final concentration
of 1 μg/mL followed by addition of carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP) (Sigma-Al-
drich) to a concentration of 0.5 μM. Finally, a mixture of
myxothiazol (Myx, Sigma-Aldrich) and rotenone (Rot,
Sigma-Aldrich) were added to a final concentration of
0.5 μM and 1 μM respectively to inhibit complexes I and
III of the electron transport chain.Measurement of oxidative stress
Oxidative stress was measured by the fluorescent indicator
2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA, Life
Technologies). Briefly, cells were seeded in triplicate in tis-
sue culture-treated 15-mm plates at 500,000 cells per plate
in 3 mL of their respective media. After allowing the cells
to recover for 48 hours, the media was aspirated and re-
placed with 3 mL of low serum media containing 30 μM C-
6 or DMSO as a vehicle control for 3, 6, 12, 24, or 48 hours.
Following the completion of treatment, the media was dis-
carded and replaced with 1 mL of Hank’s balanced salt so-
lution (HBSS) containing 30 μM H2DCFDA and the cells
incubated for 30 minutes at 37°C. The staining media was
then discarded and the cells trypsinized and analyzed by a
FACscan flow cytometer (Becton Dickinson, Mountain
View, CA, USA) for fluorescence.Real-time PCR (RT-PCR)
For experiments designed to measure gene expression,
real-time PCR (RT-PCR) was conducted using a LightCy-
cler 480 (Roche, Basel, Switzerland). Following drug treat-
ment, RNA was isolated using an RNeasy RNA isolation
and purification kit (Qiagen) per the manufacturer’s
protocol. Genomic DNA was removed with a DNase di-
gest and 1 μg of RNA was used to synthesize cDNA using
a Superscript III Reverse Transcriptase kit from Invitrogen
per the manufacturer’s protocol; after an RNase H diges-
tion, RT-PCR was performed in a 5 μL reaction using
KAPA SYBR FAST qPCR Master Mix (Kapa Biosystems,
Boston, MA, USA). The following primer sets were used:
CHOP 5′-AGTCTCTCCTCGGCTTGC-3′ and 5′-ACATC
TGGGAGAAAGGTTGTC-3′ [5]. Data were normalized
to an internal reference gene (GAPDH 5′-AAATTCCATG
GCACCGTC-3′ and 5′-GATGGTGATGGGATTTCCA-
3′) and relative gene expression was assessed using the
comparative CT method [6].Measurement of caspase activity
Caspase activity was measured using the Caspase-Glo assay
(Promega) for caspases 3/7, 8, and 9 according to the man-
ufacturer’s protocol.Ethical considerations
No human or animal experiments were conducted; ethical
approval from an independent review committee was not
required for the studies conducted and presented herein.Statistics
For in vitro assays, an unpaired Student’s t test was per-
formed using GraphPad Prism 6.0 or Microsoft Excel
(Microsoft, Redmond, WA, USA) and P values <0.05 be-
tween groups were considered significant.
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The cytotoxic molecule C-6 is selective for cancer cells
In a previous report, we identified a novel diarylmethine-
containing small molecule, C-6, that selectively kills breast
cancer cells (Figure 1A) [2]. Specifically, the small mol-
ecule was found to be cytotoxic against chemoresistant
patient-derived primary cells in addition to multiple breast
cancer cell lines at low micromolar concentrations. This
cytotoxicity against malignant cells was found to be in
contrast to the largely benign effect of C-6 against in vitro
models of normal mammary epithelial tissue (Figure 1B).
Expression profiling reveals C-6 induces mitochondrial
and endoplasmic reticulum stress pathways
As a first approach toward further characterizing C-6’s
mechanism of action and understanding the biological
basis for its cancer selectivity, a next-generation RNA se-
quencing experiment was conducted to profile the tran-
scriptome following C-6 treatment. MCF-7 breast cancer
cells were treated in triplicate with either 30 μM C-6 or
a matched DMSO vehicle control for 3 hours. Following
RNA isolation and subsequent sequencing, a differentialFigure 1 Characterization of C-6-induced endoplasmic reticulum (ER)
analysis of C6-treated MCF-7 breast cancer cells and MCF-10A mammary ep
deviation of three replicates. (C) Analysis of the 20 most differentially expre
3-hour treatment with 30 μM C-6 (in triplicate). Results are plotted as a log
analysis of proteins associated with the ER stress response pathway followiexpression analysis was performed to identify transcrip-
tional changes resulting from treatment with the small
molecule (Figure 1C). Of the nearly 18,000 genes pro-
filed in the experiment, 68 genes were found to have sta-
tistically significant differences in their expression levels
compared to the control samples. Interestingly, seven of
the top twenty genes whose expression was upregulated
compared to controls were associated with endoplasmic
reticulum (ER) stress response pathways [7-11]. Add-
itionally, six of the twenty most downregulated genes
were encoded by the mitochondrial genome, suggesting
mitochondrial stress as a component in C-6’s phenotype.
In order to determine if ER stress response genes identi-
fied from the MCF-7 transcriptome profiling experiment
were upregulated at the protein level, known ER stress pro-
teins were assayed by Western blot in three breast cancer
cell lines (MCF-7, T47D, and MDA-MB-231) and one nor-
mal mammary epithelial cell line (MCF-10A) (Figure 1D);
the results of the Western blots were also quantified by
densitometric analysis (Additional file 2). A time-course
treatment study over 48 hours using 30 μM C-6 revealed
that the expression of DDIT3 (CCAAT-enhancer-bindingstress. (A) The anticancer small molecule C-6. (B) A dose-response
ithelial cells measuring cell viability. Error bars represent the ± standard
ssed (upregulated and downregulated) MCF-7 transcripts following a
2 ratio of the treated versus control samples. (D) Protein expression
ng a time course treatment with 30 μM C-6.
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whose expression during ER stress can promote cell death,
was increased markedly in the MCF-7 and T47D cell lines
but was not detected in the MCF-10A or MDA-MB-231
cell lines [12]. GRP78, a protein-folding chaperone in the
ER whose expression is frequently increased during periods
of protein misfolding, was increased in MCF-7, T47D, and
MDA-MB-231 breast cancer cell lines but not in the C-6-
insensitive MCF-10A normal mammary epithelial cell line
[13]. The relative levels and phosphorylation status of
EIF2α, which is phosphorylated upon induction of ER
stress, were also analyzed by Western blot following treat-
ment with C-6 [14]. We found that EIF2α was phosphory-
lated in all of the cell lines examined but to varying degrees.
A relatively high basal level of EIF2α phosphorylation was
also observed in the three cancer cell lines compared to the
normal mammary epithelial cell line. Finally, the phosphor-
ylation of c-Jun Kinase (JNK) was measured following a
time-course treatment with C-6. The JNK pathway can be
activated by the accumulation of unfolded proteins in the
lumen of the ER and JNK signaling has been shown to
potentiate pro-death pathways [15-18]. A striking increase
in phosphorylation was observed in MCF-10A and MCF-
7 cells after 1 hour of C-6 treatment; T47D and MDA-
MB-231 cells also presented with an increase in JNK
phosphorylation but this effect was attenuated compared
with MCF-10A and MCF-7 cells. Collectively, differential
gene expression profiling and protein expression measure-
ments reveal ER stress to be a component of C-6’s bio-
logical activity although the magnitude of this response
was found to vary between cell types. These data suggest a
possible role for mitochondrial and ER stress in C-6-
induced cell death.
C-6 induces mitochondrial enlargement
During our efforts to define the mechanism by which C-6
induces caspase-independent cell death in breast cancer
cells, a unique cytoplasmic vacuole phenotype was observed
in MCF-7, T47D, and MDA-MB-231 cells upon treatment
with 30 μM C-6 but not in MCF-10A cells (Figure 2A and
Additional file 3). The effect was apparent by phase micros-
copy beginning 3 hours after the start of treatment and be-
came prominent after 24 hours. This cytoplasmic vacuole
phenotype is consistent with reports of paraptosis, a form of
caspase-independent programmed cell death first character-
ized by Sperandio and coworkers [19]. In agreement with
this report, the C-6-induced vacuole phenotype was com-
pletely blocked when cells were co-treated with C-6 and
inhibitors of transcription, ACTD, or translation, CHX
(Additional file 3). The paraptotic form of programmed cell
death has also been associated with defects in mitochondrial
and ER morphology and function [19,20]. As such, C-6-
treated cells were analyzed by TEM to characterize mito-
chondrial and ER morphology. MCF-10A and MCF-7 cellswere treated with 30 μM C-6 or a matched DMSO vehicle
control for 24 hours then imaged by TEM. Interestingly, C-
6-insensitive MCF-10A cells displayed no apparent differ-
ences between treated and control samples; however, signifi-
cant ER and mitochondrial defects were observed in C-6-
treated MCF-7 cells (Figure 2B). Consistent with published
reports of paraptotic cell death, the defects observed when
compared to control-treated MCF-7 cells included mito-
chondrial enlargement, substantial cristae disruption, in-
creased mitochondrial matrix volume, and the presence of
distended ER [21,22]. These data further support the in-
volvement of ER and mitochondrial stress in C-6’s mechan-
ism of action against cancer cells, and suggest cell death
may be mediated through paraptosis.
Metabolic imbalances occur following treatment with C-6
The observation that C-6-treated MCF-7 cells present
with significant morphological defects of the mitochondria
led us to assess mitochondrial function using metabolomic
profiling of tricarboxylic acid (TCA) cycle intermediates.
In order to measure acute changes in metabolic function
following treatment with the small molecule, MCF-10A
and MCF-7 cells were treated for 3 hours with 30 μM C-6
or a matched DMSO vehicle control. It was discovered
that MCF-10A cells exhibited a statistically significant
decrease in NADPH, acetyl-coenzyme A (CoA), and
succinyl-CoA and an increase in NADH while MCF-7
cells displayed an increase in AMP and a decrease in the
level of succinyl-CoA (Figure 3A). The metabolic interme-
diates measured in the experiment suggest functional de-
fects in cellular energy production and also that MCF-10A
cells, while insensitive to the cytotoxic effects of C-6, also
experience altered energy metabolism as a result of C-6
treatment.
Treatment with C-6 decreases rates of mitochondrial
oxygen consumption
The altered metabolic profile observed in C-6-treated cells
in conjunction with the mitochondrial defects identified
by TEM prompted further studies to characterize the ef-
fects of C-6 on mitochondrial energy production. Oxygen
consumption and ECARs were measured in MCF-10A,
MCF-7, T47D, and MDA-MB-231 cells following a time-
course treatment with either 30 μM C-6 or a matched
DMSO vehicle control (Figure 3B). In each of the four cell
lines examined, treatment with C-6 resulted in at least a
50% reduction in rates of basal oxygen consumption at
the earliest time point tested. Specifically, MCF-10A,
MDA-MB-231, and MCF-7 basal oxygen consumption
was reduced by 54%, 58%, and 67% respectively while
T47D cell basal respiration was dramatically reduced by
92% after only 3 hours of C-6 treatment. Longer C-6 treat-
ment times (24 hours) resulted in an almost complete in-
hibition of oxygen consumption in every cell line. Despite
Figure 2 C-6 affects mitochondrial morphology. (A) Phase contrast images of MCF-10A, MCF-7, and T47D cells following treatment with either
30 μM C-6 or a matched dimethyl sulfoxide (DMSO) vehicle control. Scale bar represents 10 μm. (B) Transmission electron microscopy images
MCF-10A and MCF-7 cells following treatment with either 30 μM C-6 or a matched DMSO vehicle control for 24 hours. Arrows denote
mitochondria.
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were largely unchanged in three of the cell lines examined.
In an effort to further characterize the acute effect of C-6
on respiration, the OCR of MCF-7 cells was measured
simultaneously with the initiation of treatment. The re-
sults revealed that OCRs decreased within minutes follow-
ing the addition of 30 μM C-6 and continued to decline
for 2 hours before plateauing at approximately 50% of the
starting basal levels (Figure 3C).
Experiments were also conducted to assess the function-
ality of the electron transport chain in the presence of
C-6. While measuring OCRs, Oligo, FCCP, and a combin-
ation of Rot and Myx were added sequentially to the cells
to assess the integrity of the electron transport chain and
mitochondrial membrane potential [23]. Upon addition of
Oligo, an inhibitor of ATP synthase, a decrease in oxygen
consumption was observed in cell lines that maintained
detectable respiration, suggesting that ATP synthesis oc-
curs in conjunction with oxygen consumption and that C-
6 does not uncouple energy production from electron
transport [24]. The cells were then treated with FCCP to
uncouple respiration followed by treatment with a
combination of Rot and Myx to inhibit complex I and III
activity, respectively. Of the cell lines that maintained de-
tectable levels of oxygen consumption, the addition of
FCCP resulted in an expected increase in oxygen con-
sumption above basal levels and the addition of Rot andMyx resulted in the complete inhibition of mitochondrial
respiration. Together, these data suggest that C-6-treated
cells experience a time-dependent reduction in their cap-
acity for oxidative phosphorylation even though the cells
possess an intact and functional mitochondrial electron
transport chain.Oxidative stress accompanies C-6 treatment in cancer
cell lines
Considering the marked effect of C-6 treatment on mito-
chondrial morphology and oxidative phosphorylation, and
the connection between dysfunctional mitochondria and
production of reactive oxygen species (ROS), subsequent
studies were conducted to assess levels of oxidative stress
following treatment with the small molecule [25,26].
MCF-10A, MCF-7, T47D, and MDA-MB-231 cells were
treated with either 30 μM C-6 or a matched DMSO
vehicle control for up to 48 hours and oxidative stress was
then measured by flow cytometry following incubation
with the ROS indicator H2DCFDA. After 48 hours of
treatment with C-6, only the cancer cell lines displayed sta-
tistically significant increases in oxidative stress (Figure 3D).
In contrast, the normal mammary epithelial cell line exam-
ined did not show any significant ROS accumulation. These
data are consistent with a role of oxidative stress in
caspase-independent cell death and further suggest that
Figure 3 C-6 disrupts metabolic homeostasis and energy production. (A) Metabolomic analysis of tricarboxylic acid (TCA) cycle intermediates
following a 3-hour treatment with 30 μM C-6 or a matched dimethyl sulfoxide (DMSO) vehicle control. Values represent the average of six replicates.
(B) Measurement of oxygen consumption and extracellular acidification rates following pretreatment of cells with C-6. (C) Measurement of oxygen
consumption rates of MCF-7 cells with simultaneous addition of 30 μM C-6. (D) Quantification of : 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA)
oxidation by flow cytometry analysis. Normalized values represent the average mean fluorescence and ± standard deviation of three independent
replicates. Asterisks, * and **, denote P values <0.05 and 0.01, respectively.
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lectively kill cancer cells [27-29].
Structural modifications to C-6 can improve potency and
cancer selectivity
In order to prepare analogs of C-6 with solubility profiles
suited for intravenous injection, structure-activity relation-
ship studies were conducted to assess the compound’s toler-
ance to modifications. Twelve analogs were designed to
probe functional group tolerance on both the A-ring and B-
ring of C-6 as well as the diarylmethine position (Figure 4A).
Following their syntheses, the analogs were evaluated againstFigure 4 Structural modifications alter C-6’s cancer selectivity. (A) Ana
(B) The effects of C-6 structural modifications on potency and cancer selec
of three replicates and error bars represent the ± standard deviation of theMCF-10A and MCF-7 cells in a 12-point dose-response
assay to measure cell viability (Figure 4B). These cell lines
were selected as models to identify cytotoxic analogs that
retained cancer-selective profiles. By modifying the position
of the aniline group on the A-ring, we found that when the
nitrogen resides at the meta position (analog 1), a more po-
tent and cancer-selective profile could be obtained com-
pared to the parent molecule. However, conversion of C-6’s
carbamate ester to an aryl sulfonamide resulted in a
complete loss of selectivity (analogs 2 and 3); replacing the
tert-butyl group of the carbamate with a methyl group also
attenuated the cancer-selective phenotype but to a lesserlogs of C-6 designed with modifications to both the A-ring and B-ring.
tivity as measured in a cell viability assay. Values represent the average
se replicates.
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http://breast-cancer-research.com/content/16/6/472degree (analog 4). Of the synthetic changes made to the B-
ring of C-6, removal of the two methoxy substituents (ana-
log 5) or replacement of one methoxy group with an alcohol
resulted in decreased efficacy. Modifying these same posi-
tions on the B-ring to include propargyl groups (analogs 7
and 8) resulted in slightly improved potencies and cytotoxic
effects limited largely to the cancer cells; the para-carbox-
ylic acid compound (analog 9) displayed a significant loss in
potency in the cell viability assay. Finally, C-6 analogs con-
taining modifications to the diarylmethine carbon were pre-
pared and tested in vitro. A reduction in cancer selectivity
was observed upon incorporation of a hydroxyl group at
this position (analogs 10 and 11) and the presence of a
structurally rigid alkene at the diarylmethine position (ana-
log 12) had a minimal effect on the analog’s EC50 compared
to the parent molecule. Collectively, the structural studies
indicate that while C-6’s potency can tolerate a variety of
functional group modifications, the cancer-selective pheno-
type is especially sensitive to these alterations.
Upon finding that several of the analogs either retained
or improved upon the cancer-selective nature of the par-
ent molecule C-6, studies were conducted to determine
whether these analogs affected the same biological path-
ways as C-6. The three most potent and cancer-selective
analogs (Analog 1, Analog 8, and Analog 12) were used in
a panel of experiments to assess mechanistic similarities
with C-6. The experiments were designed to evaluate the
following characteristics in T47D cells: ER stress as mea-
sured by RT-PCR analyses of the transcript CHOP, cyto-
plasmic vacuole formation and mitochondrial swelling,
caspase activation, mitochondrial functionality and oxygen
consumption, and oxidative stress. In each of the experi-
ments performed, the three analogs tested resulted in
similar findings as with the parent molecule C-6
(Additional file 4). Based upon these findings, it is there-
fore likely that the cancer-selective analogs modulate the
same biological pathways as C-6, resulting in an ER stress
response and mitochondrial dysfunction.
Discussion
In a previous report, our laboratories identified from a
chemical library screen a small molecule that was both
cytotoxic against and selective for cancer cells. Specifically,
we demonstrated that the small molecule C-6 was capable
of killing highly metastatic primary pleural effusion cells
acquired from patients with chemoresistant breast cancer,
and that the mechanism of cell death was independent of
caspase activity. Since tumor cells can be defined by their
ability to evade apoptosis [30,31], non-apoptotic cell death
pathways may provide alternative mechanisms by which
to therapeutically target cancer cells. C-6’s unique pheno-
type and strong selectivity profile prompted us to expand
our mechanistic studies with the goal of characterizing
this non-apoptotic cell death pathway.As a first step toward this goal, we conducted an RNA-
seq experiment that demonstrated the expression of ER
stress response genes was substantially upregulated and
multiple genes encoded by the mitochondrial genome
were significantly decreased after only 3 hours of treat-
ment. Furthermore, Western blot analyses of four differ-
ent ER stress-related proteins revealed that the induction
of ER stress was common in all C-6-treated cells, although
the magnitude of the stress response was varied in each of
the cell types tested. Higher cancer cell proliferation rates
and concomitant demands for new protein synthesis result
in an increased burden on the protein folding machinery
of the ER; in addition, glucose dyshomeostasis and hyp-
oxia associated with the tumor microenvironment con-
tribute to this burden by promoting protein misfolding
and inhibiting proper glycosylation [32,33]. As such, the
presence of sustained ER stress has been established in
many types of cancer and the pathway has been the focus
of anticancer drug development [34-38]. In accordance
with these observations, it is reasonable to consider cancer
cells as being more sensitive to this perturbation while
nonmalignant cells have a greater capacity to survive dur-
ing periods of decreased protein translation. Further con-
sidering the role of ER stress in C-6-induced cell death, it
is interesting to note that multiple signaling arms of the
unfolded protein response (UPR) can be activated during
periods of ER stress and interplay between these signaling
pathways is directly responsible for the activation of either
pro-survival or pro-death pathways (reviewed in [39]).
The presence of multiple UPR signaling arms and the nat-
urally occurring variation between cell types provides a
reasonable explanation for disparities in the magnitude of
the ER stress response observed between the cell lines ex-
amined. It is therefore possible that C-6 can differentially
activate ER stress response pathways depending upon the
predisposition of the cell line utilized.
We also demonstrated that C-6 has a considerable ef-
fect on mitochondrial morphology and function. TEM
images revealed gross morphological changes to the
mitochondria of C-6-treated MCF-7 cells; however, this
effect was not observed in the normal mammary epithe-
lial cell line examined. We were therefore surprised to
find that MCF-10A cells experience metabolic dysho-
meostasis and defects in oxidative phosphorylation in a
similar manner to three cancer cell lines following C-6
treatment. However, a differential response between the
normal epithelial cell line and malignant cell lines was
established on the basis of ROS production. Upon treat-
ment with C-6 for 48 hours, MCF-7, T47D, and MDA-
MB-231 cells experience significantly higher levels of
oxidative stress than the MCF-10A cells. These results
demonstrate that C-6 has the ability to affect mitochon-
drial energy production and suggest that ROS could play
a role in the cancer-selective nature of C-6.
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to C-6 and the effects of these scaffold modifications on
the small molecule’s potency and cancer selectivity. Using
MCF-10A and MCF-7 cells to model the biological activ-
ity of the analogs, we found that, with the exception of the
para-carboxylic acid compound (analog 9), every analog
was cytotoxic against the MCF-7 breast cancer cells
with an EC50 less than 30 μM. In contrast, the cancer-
selectivity profiles showed considerable variability. Nearly
half of the structural alterations made to the parent mol-
ecule resulted in a diminished or complete loss of selectiv-
ity for cancer cells. Overall, these data establish that while
scaffold modification is most likely to affect C-6’s cancer-
specific cytotoxicity, C-6 analogs with excellent selectivity
profiles and potencies that surpass the parent molecule
can be synthesized. Additional experiments designed to
assess mechanistic similarities between the three most
cancer-selective analogs and the parent molecule were also
conducted. Not unexpectedly, the results of these studies
suggested that the analogs affect the same biological
pathways as C-6. Based on these results, it is reasonable to
consider that C-6 could be amenable to modifications sup-
porting affinity-based target identification studies.Conclusions
The collective results of our investigation into C-6’s
mechanism of action support a role for the induction of
mitochondrial and ER stress and demonstrate that these
stressors are a component of C-6’s biological activity. The
results of the study also establish that caspase-independent
cell death promoted by C-6 occurs concomitantly with the
induction of oxidative stress, suggesting a role for oxidative
dyshomeostasis in the cancer-selective nature of the small
molecule. Finally, C-6 analogs were designed to explore the
functional group tolerance of the molecule in cell viability
assays. These structure-activity relationship studies revealed
that analogs with cancer-selective properties and improved
anticancer effects as compared to the parent molecule
could be generated and that these analogs retained the
same biological activity; these results also inform the design
of molecules for fluorophore- and affinity-based target
identification studies.Additional files
Additional file 1: Synthesis of C-6 and C-6 analogs.
Additional file 2: Densiometric analyses of western blots probing
ER stress proteins. Densiometric plots were generated from the data
presented in Figure 1D. The analysis was conducted by normalizing each
protein band to its respective loading control.
Additional file 3: Inhibition of C-6-induced cytoplamic vacuolation
by inhibitors of transcription and translation. MCF-7, T47D, and
MDA-MB-231 cells were treated with C-6 (30 μM) for 24 hours with or
without inhibitors of transcription (actinomycin D, ACTD) or translation(cycloheximide, CHX). Cells were then stained with MitoTracker and live
imaging was conducted to assess mitochondrial morphology.
Additional file 4: Mechanistic studies of C-6 analogs. (A) T47D cells
were treated with C-6 (or analogs) for 24 hours, stained with MitoTracker,
then imaged as live cells to assess mitochondrial morphology. (B) T47D
cells were treated for 24 hours with either 30 μM C-6 or 30 μM of analog
1, 8, or 12 then CHOP gene expression was measured by real-time PCR.
(C) Caspase 3/7, 8, and 9 activity was measured in T47D cells following
72 hours of small molecule treatment (each at 30 μM) or 18 hours of
staurosporine (1 μM) treatment using the Promega Caspase-Glo assay
system. (D) Measurement of oxygen consumption rates following
pre-treatment of cells with either C-6 or analogs 1, 8, or 12 (each at 30
μM) for 24 hours. (E) Measurement of oxidative stress by DCF staining
following 48 hours of treatment with 30 μM compound.
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